CYP3A activity based on plasma 4β-hydroxycholesterol during the early postpartum period has an effect on the plasma disposition of amlodipine

Drug Metab Pharmacokinet. 2015 Dec;30(6):419-24. doi: 10.1016/j.dmpk.2015.08.008. Epub 2015 Sep 3.

Abstract

This study aimed to evaluate plasma 4β-hydroxycholesterol as an endogenous marker of CYP3A4/5 activity in early postpartum women and its impact on the plasma disposition of amlodipine. Twenty-seven early postpartum women treated with amlodipine for pregnancy-induced hypertension were enrolled. The plasma concentration of 4β-hydroxycholesterol and its ratio to cholesterol in postpartum and in non-perinatal women were evaluated. The predose plasma concentration of amlodipine was determined at steady state. The medians of the plasma 4β-hydroxycholesterol concentration at day 0-3 and 8-21 after delivery were 146 and 161 ng/mL, respectively. No significant difference was observed in the plasma concentration of 4β-hydroxycholesterol between the postpartum periods. The plasma concentration of 4β-hydroxycholesterol and its ratio to cholesterol in postpartum women were significantly higher than those in non-perinatal women. A large individual variability was observed in the dose-normalized plasma concentration of amlodipine in early postpartum women. A weak negative correlation was observed between the dose-normalized plasma concentration of amlodipine and the plasma concentration of 4β-hydroxycholesterol. In conclusion, early postpartum women possessed higher CYP3A activity based on plasma 4β-hydroxycholesterol and had a large pharmacokinetic variability in amlodipine. CYP3A activity during the early postpartum period had an effect on the plasma disposition of amlodipine.

Keywords: 4β-hydroxycholesterol; Amlodipine; CYP3A; Pharmacokinetics; Pregnancy; Pregnancy-induced hypertension.

Publication types

  • Observational Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Amlodipine / administration & dosage
  • Amlodipine / blood
  • Amlodipine / pharmacokinetics*
  • Antihypertensive Agents / administration & dosage
  • Antihypertensive Agents / blood
  • Antihypertensive Agents / pharmacokinetics*
  • Biomarkers / blood
  • Biotransformation
  • Calcium Channel Blockers / administration & dosage
  • Calcium Channel Blockers / blood
  • Calcium Channel Blockers / pharmacokinetics*
  • Cytochrome P-450 CYP3A / metabolism*
  • Female
  • Humans
  • Hydroxycholesterols / blood*
  • Hypertension, Pregnancy-Induced / blood
  • Hypertension, Pregnancy-Induced / diagnosis
  • Hypertension, Pregnancy-Induced / drug therapy*
  • Hypertension, Pregnancy-Induced / enzymology
  • Postpartum Period / blood*
  • Pregnancy
  • Substrate Specificity
  • Up-Regulation

Substances

  • Antihypertensive Agents
  • Biomarkers
  • Calcium Channel Blockers
  • Hydroxycholesterols
  • cholest-5-ene-3,4-diol
  • Amlodipine
  • CYP3A5 protein, human
  • Cytochrome P-450 CYP3A
  • CYP3A4 protein, human